Announcement on Conducting Foreign Exchange Hedging Business
Filed with SSE · · 5 pages · Chinese
Sichuan Huiyu Pharmaceutical Co. Ltd. on 6ix
Earlier from Sichuan Huiyu Pharmaceutical
- Correction Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of Approval of Etoposide Injection and Fluorouracil Injection by the U.S. FDA
- Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDA
- Announcement on Result of Passive Shareholding Reduction by Shareholder with Over 5% Shares
Later from Sichuan Huiyu Pharmaceutical
- Announcement on Voluntary Disclosure of Drug Registration Certificate Obtained for Carfilzomib for Injection
- Announcement on Shareholding Reduction Plan for Shareholders
- Announcement on Abnormal Fluctuations in Stock Trading
- Indicative Announcement on Postponing Term Change of the Board of Directors and Term Expiration of Partial Independent Directors
- Announcement on Voluntary Disclosure of Notice of Acceptance for Drug Clinical Trial Application Obtained by HY-1016 Sustain-released Injection
Follow Sichuan Huiyu Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Huiyu Pharmaceutical